Plain-English translation of NCT07400289 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
Researchers are testing a new single-probe FibroScan device that measures how stiff your liver is—a key sign of liver damage. This trial will compare how well this new single probe works compared to the current standard probes used in clinics. If the new probe works just as well, it could make liver exams simpler and more convenient for patients.
Currently, doctors use multiple probes of different sizes to measure liver stiffness in patients with chronic liver disease. This trial exists to see whether a single probe could do the job just as accurately, which would streamline the examination process and make it easier for patients to get tested.
You likely qualify if…
You likely don't qualify if…
You will visit a hepatology clinic at one of the participating sites in France or Hong Kong for a liver ultrasound examination. During your visit, doctors will perform the standard liver stiffness measurement using both the current probes and the new single probe, so they can compare how well each one works. The exam itself is non-invasive and painless—it typically takes about 15–30 minutes.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
France
Hong Kong
Sponsor
Echosens
Collaborators
Novotech CRO
Enrollment target
~309 participants
Started
November 2025
Primary completion
November 2026
Age range
18 Years and older
Last updated on clinicaltrials.gov in February 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Anne Llorca
Echosens
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.